Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study

Abstract

The goal of treatment in patients with pulmonary arterial hypertension is to achieve a low risk status, indicating a favorable long-term outcome. The REPLACE study investigated the efficacy of switching to riociguat in patients with pulmonary arterial hypertension and an insufficient response to phosphodiesterase-5 inhibitors. In this post hoc analysis, we applied the REPLACE composite endpoint of clinical improvement to the placebo-controlled PATENT-1 study of riociguat in pulmonary arterial hypertension and its long-term extension, PATENT-2. Clinical improvement was defined as ≥2 of the following in patients who completed the study without clinical worsening: ≥10% or ≥30 m improvement in 6-minute walking distance; World Health Organization functional class I or II; ≥30% decrease in N-terminal prohormone of brain natriuretic peptide. At PATENT-1 Week 12, patients treated with riociguat were more likely to achieve the composite endpoint vs. placebo (P < 0.0001), with similar results in pretreated (P = 0.0189) and treatment-naïve (P < 0.0001) patients. Achievement of the composite endpoint at Week 12 was associated with a 45% reduction in relative risk of death and a 19% reduction in relative risk of clinical worsening in PATENT-2. Overall, these data suggest that use of the REPLACE composite endpoint in patients with pulmonary arterial hypertension is a valid assessment of response to treatment.

Read the full article online

Topics

Pulmonary Arterial Hypertension
Survival

Authors

Gérald Simonneau, Hossein-Ardeschir Ghofrani, Paul A. Corris, Stephan Rosenkranz, Ekkehard Grünig, Jim White, Vallerie V. McLaughlin, David Langleben, Christian Meier, Dennis Busse, Frank Kleinjung, Raymond L. Benza

Published in:

Pulmonary Circulation Vol 10: No 4 cover image

October 2020

Pulmonary Circulation Vol 10: No 4

View this journal

Related articles


Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.

Authors: Mandras S, Kovacs G, Olschewski H, Broderick M, Nelsen A, Shen E, Champion H Source: J Cardiovasc Pharmacol Ther

Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension.

Authors: Masaki T, Okazawa M, Asano R, Inagaki T, Ishibashi T, Yamagishi A, Umeki-Mizushima S, Nishimura M, Manabe Y, Ishibashi-Ueda H, Shirai M, Tsuchimochi H, Pearson JT, Kumanogoh A, Sakata Y, Ogo T, Kishimoto T, Nakaoka Y Source: Proc Natl Acad Sci U S A

Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension.

Authors: Gairhe S, Awad KS, Dougherty EJ, Ferreyra GA, Wang S, Yu ZX, Takeda K, Demirkale CY, Torabi-Parizi P, Austin ED, Elinoff JM, Danner RL Source: Proc Natl Acad Sci U S A

Inverse modeling framework for characterizing patient-specific microstructural changes in the pulmonary arteries.

Authors: Pourmodheji R, Jiang Z, Tossas-Betancourt C, Figueroa CA, Baek S, Lee LC Source: J Mech Behav Biomed Mater

Up-regulation of the long non-coding RNA Xist and the imbalance sex/ratio of pulmonary arterial hypertension.

Authors: Qin S, Predescu D, Carman B, Patel P, Chen J, Kim M, Lahm T, Geraci M, Predescu S Source: Am J Pathol

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg